Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The goal of this interventional study is to evaluate the efficacy of APG-157 in combination
with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study
aims to answer are:
- Progression-free and overall survival of patients receiving this combination;
- Quality of Life (QOL); and
- Tumor response on imaging
The participants will take APG-157 daily by dissolving two pastilles in their mouth at around
breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in
the mouth.
The participants will continue to receive Bevacizumab as standard of care.